Deepinder Goyal, co-founder of food delivery platform Zomato, has announced that his health-tech startup Temple has discovered a new biomarker called Entropy that measures the body’s real-time metabolic cost. The announcement came on June 18, 2026, through posts on X and LinkedIn.
Temple, the startup founded by Goyal, identified Entropy as a biomarker that can only be read from the temple region of the body. The metric updates every second and appears as a live number on Temple’s home screen, operating on an index from 1 to 250. According to the company, a score of 1 represents the deepest rest state seen in mediators, while 250 indicates peak output levels typical of elite athletes.
The biomarker tracks energy expenditure continuously, providing what Goyal describes as the real-time cost of being alive. Temple claims Entropy tracks metabolism more closely than traditional heart rate monitoring, citing a correlation coefficient of r=0.93 for Entropy versus r=0.55 for heart rate. Factors that affect Entropy readings include sleep, stress, exercise, meals, caffeine consumption, cold exposure, meditation, and strength training.
The Temple device is a precision instrument designed to be worn at the temple region. The company describes it as providing richer insights and a cleaner signal into body physiology compared to existing wearable technology. The startup is currently accepting early access applications for the device, though no commercial launch timeline or pricing information has been disclosed.
Goyal’s involvement in health technology extends beyond Temple. He has previously shared research on what he calls the Gravity Ageing Hypothesis, which centers on tracking cerebral blood flow as a biomarker for aging and cognition. The Temple device was initially developed as an experimental tool to calculate brain flow accurately in real-time during this research.
Medical experts have questioned the scientific validity of Temple’s claims. Dr. Suvrankar Datta, a senior radiologist and AI researcher at AIIMS Delhi, stated on X that the device currently has no scientific standing as a useful medical device. The Temple device remains a private research tool and is not yet available for public sale.
The company positions itself away from EEG-heavy consumer neurotech approaches, instead emphasizing cerebral blood flow monitoring as its core technology.
The Temple team has made a breakthrough.
We have discovered (literally discovered) a biomarker, only readable on the temple region, and nowhere else, that measures the real-time cost of you being alive.
We are calling it Entropy™.
It's a live number on Temple's home screen,… pic.twitter.com/wEOu29hVBf
— Deepinder Goyal (@deepigoyal) June 18, 2026
Read Article: India and South Korea Deepen Startup Ties With New Venture Capital Partnership
